Paxlovid is an antiviral combination therapy that can reduce the risk of COVID-19 causing severe illness, hospitalization and ...

FDA revises emergency use authorization for Pfizer's Paxlovid, impacting distribution and treatment of mild-to-moderate COVID-19. Transitions from March 8.

COVID-19 cases are rising in more than half of states. Is the US in a summer wave? What to know about COVID trends and ...

June 7 (Reuters) - A 15-day course of Pfizer's , opens new tab COVID-19 antiviral treatment Paxlovid did not relieve symptoms of long COVID, according a study by Stanford University researchers.

Paxlovid made no significant improvement to long COVID symptoms, including fatigue, brain fog and body aches. The finding “does not rule out” Paxlovid as a therapy, the researchers wrote.

The Paxlovid treatment is free. MORE: Don't cancel holiday plans due to COVID but take precautions, doctors say Health experts say it's a game changer and it's helping people recover more quickly.

Researchers have described the optimal timing for COVID-19 patients to take the antiviral, Paxlovid, to get the most benefit from the treatment, according to a study published April 16 in eLife.

Most people who take Paxlovid for the treatment of COVID do not get rebound COVID, but up to 20% of patients do. That doesn't mean that the drug isn't doing its job.

Pfizer and the FDA view Paxlovid as an important complementary tool to vaccination that can help high-risk Americans manage their Covid infections.

As soon as doctors determined on Thursday that President Biden had Covid-19, the White House doctor put him on the antiviral Paxlovid. Considered a game-changer when it was authorized in December ...